CAPUTO, Antonella
 Distribuzione geografica
Continente #
NA - Nord America 10.392
AS - Asia 5.750
EU - Europa 4.470
SA - Sud America 937
Continente sconosciuto - Info sul continente non disponibili 251
AF - Africa 140
OC - Oceania 20
Totale 21.960
Nazione #
US - Stati Uniti d'America 10.174
SG - Singapore 2.210
PL - Polonia 1.760
CN - Cina 1.421
BR - Brasile 718
IT - Italia 683
VN - Vietnam 637
HK - Hong Kong 457
DE - Germania 447
UA - Ucraina 441
TR - Turchia 330
GB - Regno Unito 278
FR - Francia 197
FI - Finlandia 155
RU - Federazione Russa 149
BD - Bangladesh 126
IN - India 117
SE - Svezia 110
CA - Canada 104
ID - Indonesia 96
JP - Giappone 92
AR - Argentina 89
MX - Messico 78
NL - Olanda 63
ZA - Sudafrica 49
IQ - Iraq 45
BE - Belgio 38
EC - Ecuador 35
CO - Colombia 32
PK - Pakistan 31
SA - Arabia Saudita 31
AT - Austria 28
ES - Italia 25
MA - Marocco 22
PH - Filippine 20
LT - Lituania 19
VE - Venezuela 19
MY - Malesia 18
AU - Australia 17
CL - Cile 16
CZ - Repubblica Ceca 16
KE - Kenya 16
AE - Emirati Arabi Uniti 14
EG - Egitto 14
UZ - Uzbekistan 14
PY - Paraguay 12
RO - Romania 12
TN - Tunisia 12
IE - Irlanda 11
IL - Israele 10
IR - Iran 10
JM - Giamaica 9
JO - Giordania 9
KZ - Kazakistan 9
LB - Libano 9
CH - Svizzera 8
PE - Perù 7
AL - Albania 6
CR - Costa Rica 6
TH - Thailandia 6
ET - Etiopia 5
NP - Nepal 5
OM - Oman 5
PS - Palestinian Territory 5
UY - Uruguay 5
DZ - Algeria 4
GR - Grecia 4
GT - Guatemala 4
KR - Corea 4
PA - Panama 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
BY - Bielorussia 3
HN - Honduras 3
HU - Ungheria 3
KH - Cambogia 3
MD - Moldavia 3
NG - Nigeria 3
RS - Serbia 3
SN - Senegal 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
LY - Libia 2
MG - Madagascar 2
MN - Mongolia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
ZW - Zimbabwe 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CD - Congo 1
Totale 21.696
Città #
Warsaw 1.757
Singapore 1.290
Ashburn 1.172
Fairfield 948
San Jose 772
Woodbridge 759
Houston 562
Beijing 499
Santa Clara 472
Hong Kong 448
Jacksonville 402
Seattle 387
Chandler 369
Wilmington 344
Ann Arbor 342
Cambridge 328
Izmir 237
Ferrara 207
New York 199
Ho Chi Minh City 180
Princeton 173
Nanjing 164
Los Angeles 163
Dallas 161
Hanoi 151
The Dalles 123
Lauterbourg 119
Council Bluffs 115
San Diego 108
Munich 95
Tokyo 91
Milan 81
Shanghai 66
Helsinki 61
Jakarta 59
São Paulo 57
Bologna 49
London 46
Mexico City 44
Boardman 43
Orem 43
Buffalo 42
Nanchang 41
Da Nang 40
Tianjin 40
Shenyang 37
Brussels 36
Hebei 36
Chicago 35
Rome 35
Dong Ket 34
Jiaxing 33
Montreal 33
Brooklyn 32
Changsha 32
San Francisco 30
Toronto 29
Chennai 28
Haiphong 28
Boston 27
Dearborn 27
Phoenix 27
Rio de Janeiro 27
Manchester 26
Nuremberg 26
Turku 25
Falls Church 24
Atlanta 23
Hefei 23
Stockholm 23
Norwalk 22
Belo Horizonte 21
Falkenstein 21
Frankfurt am Main 21
Jinan 21
Johannesburg 21
Mountain View 21
Amsterdam 20
Denver 19
Moscow 19
Poplar 19
Orange 18
Redwood City 17
Baghdad 16
Porto Alegre 16
Kunming 15
Modena 15
San Mateo 15
Washington 15
Des Moines 13
Mumbai 13
Nairobi 13
Ankara 12
Auburn Hills 12
Augusta 12
Bogotá 12
Brno 12
Ningbo 12
Ottawa 12
Brasília 11
Totale 15.071
Nome #
HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity 412
Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice 368
BK virus-plasmid expression vector that persists episomally in human cells and shuttles into Escherichia coli 339
Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS tat-based vaccines 316
Candidate HIV-1 Tat vaccine development: From basic science to clinical trials 313
Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide 290
Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse 281
The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters 275
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses. 274
HIV-1 tat addresses dendritic cells to induce a predominant th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection 267
An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge 266
Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys 264
Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection 262
The HIV-1 Tat protein affects human CD4+ T cell programming and activation, and favors the differentiation of naïve CD4+ T cells 242
Recombinant herpes simplex virus and uses therefor 235
Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19 232
The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS 232
Nanoparticles for delivery of a pharmacologically active agent 230
Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice 211
Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and long-lasting antigen-specific humoral and cellular responses in mice 204
Age-related decline of de novo T cell responsiveness as a cause of COVID-19 severity 201
Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine model 199
Inhibition of HIV-1 replication and reactivation from latency by tat transdominant negative mutants in the cysteine rich region 197
Episomal DNA of a BK virus variant in a human insulinoma 196
T.P.2.07 The systemic administration of a low dose of 2OMePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model 195
Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients 192
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects 192
Altered Basal Lipid Metabolism Underlies the Functional Impairment of Naive CD8+ T Cells in Elderly Humans 190
DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune response against wild-type Tat 189
High expression of exogenous cDNAs directed by HIV-1 long terminal repeat in human cells constitutively producing HIV-1 tat and adenovirus E1A/E1B 188
Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6Pcy243 187
Transformation of hamster kidney cells by fragments of BK virus DNA 185
Ageing Curtails the Diversity and Functionality of Nascent CD8+ T Cell Responses against SARS-CoV-2 184
null 183
Adenovirus type 12 early region 1A proteins repress class I HLA expression in transformed human cells 182
EFFECT OF TAT TRANSDOMINANT NEGATIVE MUTANTS ON HIV-1 REPLICATION IN JURKAT T-CELL LINES 181
null 179
Prevalence of liver tumours in HIV-1 tat-transgenic mice treated with urethane 177
Transformation of human embryonic fibroblasts by BK virus, BK virus DNA and a subgenomic BK virus DNA fragment 176
Cooperation in oncogenesis between BK virus early region gene and the activated human c-Harvey RAS oncogene 171
Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine 169
Complex associates of plasmid DNA and a novel class of block copolymers with PEG and cationic segments as new vectors for gene delivery 168
null 167
Viral Vector Expressing Tat As Immunomodulatory Molecule Represent A New Vaccine Strategy Against HSV Infection 167
The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation 165
The tat gene and protein of the human immunodeficiency virus type 1. 164
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells 163
Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein 161
Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) 155
Vaccines containing the HIV tat protein as an adjuvant for the enhancement of cytotoxic T-cell responses 154
The HIV-1 tat gene as a target for gene therapy and analysis of its role in cell proliferation 153
Antiretroviral Therapy Partially Restores Phenotypic and Metabolic Immunosenescence Features of T Cells in Hiv Infected Individuals 149
Recent Advances In The Development Of HIV-1 Tat-Based Vaccines 149
Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant 147
Nanoparticle-Mediated Delivery of Antisense Oligoribonucleotides Allows Restoration of Dystrophin Expression in the mdx Mouse 146
In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment 144
Induzione di una risposta immune in topi immunizzati con DNA plasmidici codificanti due mutanti transdominanti negativi del gene tat di HIV-1. 143
Induction of anti-Tat immune response in mice following inoculation of plasmid DNA expressing HIV-tat mutant genes. 141
The HIV-1 regulatory genes tat and rev as targets for gene therapy 140
Presenza del virus BK in sarcomi di Kaposi. 140
Co-operation in cell transformation between BK virus and the human c-Harvey-ras oncogene 138
Naïve CD8+ T-Cells Engage a Versatile Metabolic Program Upon Activation in Humans and Differ Energetically From Memory CD8+ T-Cells 137
Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles 135
Use of a Novel Peptide Welding Technology Platform for the Development of B- and T-Cell Epitope-Based Vaccines 135
Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes 134
Transactivation of BKV and SV40 early promoters by BKV and SV40 T-antigens 133
Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination 133
Formation of oligomeric free BK virus DNA is required for tandem integration of viral genomes into cellular DNA 130
Induction of malignant subcutaneous sarcomas in hamsters by a recombinant DNA containing BK virus early region and the activated human c-Harvey-ras oncogene 130
Reexamination of the coding potential of the HTLV-1 pX region 130
Inhibition of HIV-1 tat activity correlates with down-regulation of bcl-2 and results in reduction of angiogenesis and oncogenicity 130
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes 129
Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application 128
Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application 127
DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination 127
Hpv-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy 127
Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin 126
Inhibition of human immunodeficiency virus reactivation from latency by tat antisense RNA and a tat transdominant negative mutant 125
Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses 122
Constitutive expression of hiv-1 tat protein in human jurkat t cells using a bk virus vector 122
Use of replication deficient hsv-1 as a vaccine vector for the deli vary of hiv-1 tat antigen 122
Expression of hepatitis B surface antigen in human cells by a recombinant BK virus DNA vector 121
Interaction of Sp1 transcription factor with HIV-1 Tat protein: Looking for cellular partners 121
Novel Chitosan-Based Schiff Base Compounds: Chemical Characterization and Antimicrobial Activity 120
ANTIRETROVIRAL THERAPY RESTORES NAÏVE T CELL FREQUENCIES OC 8 AND FUNCTIONALITY IN PLWH 120
Transformation of hamster kidney cells by a fragment of BK virus DNA containing the entire early region 119
Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL 119
Use of microparticles for antigen delivery 119
New BK virus episomal vector for complementary DNA expression in human cells 117
The Sp1 transcription factor does not directly interact with the HIV-1 Tat protein 117
Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines 114
null 113
Oncogenicity of BK virus for immunosuppressed hamster 113
Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins 113
HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials 111
Factors afceting amplification of BK virus episomal vectors in human cells 111
null 110
Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules 109
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells 109
Vaccine development for herpes simplex viruses: A commentary of special issue editors 109
Totale 17.247
Categoria #
all - tutte 102.133
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.383
Totale 105.516


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.319 38 111 73 82 29 53 68 114 61 115 106 469
2022/2023933 140 37 54 103 130 118 59 97 113 9 47 26
2023/2024644 63 80 33 23 44 143 25 36 20 17 11 149
2024/20252.923 91 70 240 100 332 225 114 108 460 405 469 309
2025/20268.018 840 313 746 1.014 1.095 503 931 426 709 931 373 137
2026/2027240 240 0 0 0 0 0 0 0 0 0 0 0
Totale 21.960